Sangamo Therapeutics (NASDAQ:SGMO – Get Rating)‘s stock saw its “hold” rating reiterated by stock analysts Wedbush in a research note released on Sunday, TipRanks reports. They currently have a price target of $10.00 on shares of the biopharmaceutical company. Wedbush’s price target would indicate a potential upside of 69.49% from the current share price.
Several other stock analysts have also recently released reports on the stock. Stifel Nicolaus cut his price target on Sangamo Therapeutics shares from $9.00 to $6.00 and placed a “hold” rating on the stock in a Thursday, Jan. 6, research note. Zacks Investment Research upgraded Sangamo Therapeutics from a “buy” to a “hold” rating in a Thursday, Jan. 13 research note. Three analysts have rated the stock with a hold rating and three have issued a buy rating for the company’s stock. According to MarketBeat.com, Sangamo Therapeutics currently has a consensus rating of “Buy” and an average price target of $16.58.
The NASDAQ SGMO traded down $0.19 on Friday, hitting $5.90. 1,070,521 shares were traded, against an average volume of 1,453,095. The company has a 50-day moving average price of $6.48 and a 200-day moving average price of $8.24. Sangamo Therapeutics has a fifty-two-week low of $5.13 and a fifty-two-week high of $13.93. The company has a market capitalization of $859.48 million, a PE ratio of -4.65 and a beta of 1.50.
Sangamo Therapeutics (NASDAQ:SGMO – Get Rating) last reported quarterly results on Thursday, February 24. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating the Zacks consensus estimate of ($0.34) by $0.08. The company posted revenue of $27.99 million in the quarter, versus a consensus estimate of $27.36 million. Sangamo Therapeutics had a negative net margin of 167.16% and a negative return on equity of 39.90%. The company’s revenues increased by 8.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.29) EPS. Analysts expect Sangamo Therapeutics to post -1.32 EPS for the current fiscal year.
In related news, major shareholder Biogen Inc. sold 81,187 shares of the company in a transaction that took place on Thursday, December 23. The shares were sold at an average price of $8.55, for a total value of $694,148.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available via this hyperlink. Insiders have sold 157,625 shares of the company worth $1,346,371 over the past three months. 2.10% of the shares are held by insiders.
A number of hedge funds have recently changed their holdings in SGMO. Wells Fargo & Company MN increased its stake in Sangamo Therapeutics shares by 4.7% in the second quarter. Wells Fargo & Company MN now owns 690,197 shares of the biopharmaceutical company worth $8,261,000 after buying 31,242 additional shares in the last quarter. Northern Trust Corp increased its position in shares of Sangamo Therapeutics by 10.6% in the second quarter. Northern Trust Corp now owns 1,491,442 shares of the biopharmaceutical company valued at $17,853,000 after purchasing an additional 143,240 shares during the period. Vigilare Wealth Management increased its position in Sangamo Therapeutics by 111.9% during the third quarter. Vigilare Wealth Management now owns 30,300 shares of the biopharmaceutical company worth $273,000 after acquiring an additional 16,000 shares in the last quarter. Alexandria Capital LLC increased its stake in Sangamo Therapeutics by 0.5% during the third quarter. Alexandria Capital LLC now owns 960,470 shares of the biopharmaceutical company worth $8,654,000 after purchasing an additional 4,943 shares during the period. Finally, Strs Ohio increased its stake in the shares of Sangamo Therapeutics by 41.7% in the 3rd quarter. Strs Ohio now owns 57,800 shares of the biopharmaceutical company valued at $520,000 after acquiring an additional 17,000 shares during the period. Institutional investors and hedge funds own 51.99% of the company’s shares.
Sangamo Therapeutics Company Profile (Get a rating)
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company, engaged in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which includes inflammatory and autoimmune diseases.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Sangamo Therapeutics right now?
Before you consider Sangamo Therapeutics, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Sangamo Therapeutics wasn’t on the list.
While Sangamo Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here